2019 Orlando Health Second Annual Pediatric Neuro-Oncology Symposium

Join us for the Second Annual Pediatric Neuro-Oncology Symposium hosted by the Haley Center for Children’s Cancer and Blood Disorders Orlando Health Arnold Palmer Hospital for Children.

This premier event will feature presentations, neuro-oncology updates and panel discussions. The symposium is ideal for pediatric oncologists, pediatric sub-specialists, pediatricians, advanced practice providers, allied health professionals and researchers who want to further their knowledge of the latest in pediatric neuro-oncology treatment.

This activity has been approved for AMA PRA Category 1 Credits™.

Date & Time
Saturday, October 19, 2019
7:00 am – 4:00 pm

Arnold Palmer’s Bay Hill Club & Lodge
9000 Bay Hill Blvd.
Orlando, FL 32819

Registration is now open. Click here to register


Continuing Education Credits

This activity has been approved for AMA PRA Category 1 Credits™.

Cost to Attend

  • Physicians & Research Faculty: $75
  • Professionals (AT/PT/PA/ARNP/Allied Health): $50
  • Students & Trainees: Complimentary (space is limited)
  • Families: Complimentary

Cancellation Policy

Cancellations must be in writing on or before October 10, 2019 for a full refund. There will be no refunds after October 10, 2019.

Hotel Information

Rooms are available at Bay Hill Club & Lodge within a room block for $158 USD per night plus tax. Call (888) 422-9445 and mention the symposium to make reservations or click here for more information.

Hotel Address:

Arnold Palmer’s Bay Hill Club & Lodge
9000 Bay Hill Blvd.
Orlando, FL 32819


Friday, October 18, 2019
5:30 pm – 7:00 pm
Welcome Reception
Faculty, attendees and guests welcome
Please RSVP to [email protected]

Saturday, October 19, 2019
7:00 am – 8:00 am
Check-in and Registration

7:30 am – 8:15 am
Breakfast – Bay Window

8:15 am – 8:30 am
Welcome and Opening Remarks
Amy Smith, MD

8:30 am – 9:15 am
Single Cell RNAseq, Mutational Drivers and Targeted Therapy: Direction, Not Destination
Nicholas, K. Foreman, MD

9:15 am – 10:00 am
Early Phase Clinical Trials in Pediatric Neuro-Oncology
Jason Fangusaro, MD

10:00 am – 10:15 am
Break – Palm Terrace

10:15 am – 11:00 am
Optic Pathway Gliomas and Updates from the Neurofibromatosis
Clinical Trial Consortium (NFCTC)
Michael Fisher, MD

11:00 am – 11:30 am
Discussion Panel: Neurofibromatosis – Updates from Bench side to Bedside
Michael Fisher, MD, Ana Aguilar-Bonilla, MD and Jason Fangusaro, MD

11:30 am – 12:30 pm
Lunch – Bay Window

12:30 pm – 1:15 pm
The Who, What and Why of Pediatric Brain Tumors
Sonia Partap, MD

1:15 pm – 2:00 pm
Survivorship and Late Effects for Pediatric Brain Tumor Patients
Natasha Smiley, MD

2:00 pm – 2:30 pm
Discussion Panel: Family Education – Ask the Experts
Natasha Pillay-Smiley, MD, Sonia Partap, MD and Laura Wieber, MSN, APRN, FNP-BC

2:30 pm – 2:45 pm
Break – Palm Terrace

2:45 pm – 3:30 pm
Central Nervous System Tumors of Infancy
Susan Chi, MD

3:30 pm – 4:00 pm
Discussion Panel: Integrating Molecular Diagnostics Into Clinical Practice
Susan Chi, MD, Amy Smith, MD and Nicholas K. Foreman, MD



Susan Chi, MD
Dr. Chi serves as the deputy director of the pediatric neuro-oncology program and holds an appointment as a pediatric neuro-oncology assistant professor in pediatrics at Dana Farber Cancer Institute. Her clinical research focuses primarily malignant infant tumors such as Atypical Teratoid Rhabdoid Tumor (ATRT), high risk medulloblastoma and choroid plexus tumors. Dr. Chi has served as the director of clinical trials for the pediatric neuro-oncology program for 16 years.

Jason Fangusaro, MD
Dr. Fangusaro is the director of developmental therapeutics and medical director of the clinical research office at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta. He is an associate professor of pediatrics at the Emory University School of Medicine and the Carter S. Martin Endowed Chair. As a clinical member of the pediatric neuro-oncology team, he specializes in treating children with central nervous system malignancies.

Michael J. Fisher, MD, ChB, MRCO
Dr. Fisher serves as the chief of neuro-oncology, director of the neuro-oncology fellowship program and director of the neurofibromatosis program at Children’s Hospital of Philadelphia. He has a special interest in brain tumors and neurofibromatosis. His research focuses on identifying new treatments and novel biomarkers and exploring functional outcomes for children with tumors associated with NF1. Dr. Fisher currently serves as the chair of steering committee and previously served as chair of the plexiform neurofibroma committee for the NF clinical Trials Consortium (NFCTC).

Nicholas K. Foreman, MD
Dr. Foreman serves as the seebaum chair of pediatric neuro-oncology at Children’s Hospital Colorado. He has an interest in the development of clinical protocols for children with difficult to treat brain tumors. He also has lab interest concentrate on the development of novel therapies with glial tumors. He serves as the associate chief for the research section of hematology oncology at Children’s Hospital Colorado, as well as a professor of pediatrics at University of Colorado.

Sonia Partap, MD
Dr. Partap serves as a clinical associate professor for neuro-oncology, child neurology and pediatrics at Stanford University/Lucile Packard Children’s Hospital. Her research interests involve the epidemiology, treatment and diagnosis of pediatric adult brain tumors. She is also interested in long-term neurological effects and design of clinical trials to treat brain and spinal cord tumors. Dr. Partap serves on the Young Professional Advisory Council for Greater Bay Area Make-A-Wish Foundation. She collaborated with the University of Melbourne to create a pediatric brain tumor program in Hanoi, Vietnam.

Natasha Pillay-Smiley, DO
Dr. Pillay-Smiley currently works at Cincinnati Children’s Hospital caring for infants, children, and young adults with brain and spinal cord tumors. Her clinical and research interests include cancer predisposition syndromes and neurofibromatosis. Dr. Pillay-Smiley’s other area of interest includes the late effects for brain and spinal cord tumor survivors.